Poly(lactic-co-glycolic) Acid-Controlled-Release Systems: Experimental and Modeling Insights

被引:302
作者
Hines, Daniel J. [1 ]
Kaplan, David L. [2 ]
机构
[1] Tufts Univ, Dept Chem & Biol Engn, Medford, MA 02155 USA
[2] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA
来源
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS | 2013年 / 30卷 / 03期
基金
美国国家卫生研究院;
关键词
PLGA; PLA; PGA; controlled release; mathematical modeling; CO-GLYCOLIC ACID; PLGA-BASED MICROPARTICLES; DRUG-RELEASE; IN-VITRO; POLYMER DEGRADATION; DELIVERY SYSTEMS; PROTEIN RELEASE; MICROSPHERES; NANOPARTICLES; MECHANISMS;
D O I
10.1615/CritRevTherDrugCarrierSyst.2013006475
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Poly(lactic-co-glycolic acid) (PLGA) has been the most successful polymeric biomaterial used in controlled drug delivery systems. There are several different chemical and physical properties of PLGA that impact the release behavior of drugs from PLGA delivery devices. These properties must be considered and optimized in the formulation of drug release devices. Mathematical modeling is a useful tool for identifying, characterizing, and predicting mechanisms of controlled release. The advantages and limitations of poly(lactic-co-glycolic acid) for controlled release are reviewed, followed by a review of current approaches in controlled-release technology that utilize PLGA. Mathematical modeling applied toward controlled-release rates from PLGA-based devices also will be discussed to provide a complete picture of a state-of-the-art understanding of the control that can be achieved with this polymeric system, as well as the limitations.
引用
收藏
页码:257 / 276
页数:20
相关论文
共 77 条
[1]   Biodegradation and biocompatibility of PLA and PLGA microspheres [J].
Anderson, JM ;
Shive, MS .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 28 (01) :5-24
[2]  
BRANNONPEPPAS L, 1993, ACS SYM SER, V520, P42
[3]   Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles [J].
Budhian, Avinash ;
Siegel, Steven J. ;
Winey, Karen I. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 346 (1-2) :151-159
[4]   Particle shape: A new design parameter for micro- and nanoscale drug delivery carriers [J].
Champion, Julie A. ;
Katare, Yogesh K. ;
Mitragotri, Samir .
JOURNAL OF CONTROLLED RELEASE, 2007, 121 (1-2) :3-9
[5]   PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery [J].
Chan, Juliana M. ;
Zhang, Liangfang ;
Yuet, Kai P. ;
Liao, Grace ;
Rhee, June-Wha ;
Langer, Robert ;
Farokhzad, Omid C. .
BIOMATERIALS, 2009, 30 (08) :1627-1634
[6]   Characterization of PLGA microspheres for the controlled delivery of IL-1 alpha for tumor immunotherapy [J].
Chen, L ;
Apte, RN ;
Cohen, S .
JOURNAL OF CONTROLLED RELEASE, 1997, 43 (2-3) :261-272
[7]   Effects of polymer degradation on drug release a mechanistic study of morphology and transport properties in 50:50 poly(dl-lactide-co-glycolide) [J].
Chiu, LK ;
Chiu, WJ ;
Cheng, YL .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 126 (1-2) :169-178
[8]   Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues [J].
Crotts, G ;
Park, TG .
JOURNAL OF MICROENCAPSULATION, 1998, 15 (06) :699-713
[9]   HISTOLOGIC COMPARISON OF POLYLACTIC AND POLYGLYCOLIC ACID SUTURES [J].
CUTRIGHT, DE ;
BEASLEY, JD ;
PEREZ, B .
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY, 1971, 32 (01) :165-+
[10]  
Drake CF, 1989, United States patent, Patent No. [US 4866097, 4866097]